Equities analysts forecast that Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Rating) will post $537.11 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Amneal Pharmaceuticals’ earnings, with estimates ranging from $528.92 million to $551.20 million. Amneal Pharmaceuticals posted sales of $535.08 million during the same quarter last year, which would indicate a positive year over year growth rate of 0.4%. The company is expected to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Amneal Pharmaceuticals will report full year sales of $2.18 billion for the current year, with estimates ranging from $2.16 billion to $2.21 billion. For the next fiscal year, analysts anticipate that the business will post sales of $2.28 billion, with estimates ranging from $2.25 billion to $2.29 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $0.10 EPS for the quarter, meeting the consensus estimate of $0.10. The business had revenue of $497.63 million during the quarter, compared to analyst estimates of $500.68 million. Amneal Pharmaceuticals had a net margin of 0.08% and a return on equity of 53.73%.
NASDAQ:AMRX opened at $3.12 on Tuesday. The business’s fifty day moving average is $4.05. The firm has a market capitalization of $940.81 million, a PE ratio of 156.00, a PEG ratio of 0.18 and a beta of 1.17. The company has a debt-to-equity ratio of 6.65, a current ratio of 2.31 and a quick ratio of 1.52. Amneal Pharmaceuticals has a fifty-two week low of $3.08 and a fifty-two week high of $6.21.
Amneal Pharmaceuticals Company Profile (Get Rating)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Institutional Support For Tyson Foods Is Growing
- Johnson Outdoors Falls On Bleak Outlook
- Time to Buy These 3 Oversold Mid-Caps
- Littelfuse Stock is Hitting on All Cylinders
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.